--- title: "Weekly Recap | GSK -3.53%, consensus target above spot" type: "News" locale: "en" url: "https://longbridge.com/en/news/298791691.md" description: "GSK fell 3.53% this week to close at $48.13, while the S&P 500 declined 0.8%, leaving the stock trailing the benchmark by roughly 2.73 percentage points. The four-session trading week showed a downward drift: Tuesday opened near $49 and marked the week’s high at $49.235, Thursday briefly dipped below $48 to $47.975, and Friday printed the week’s low at $47.85 before recovering to settle at $48.13." datetime: "2026-09-12T06:01:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298791691.md) - [en](https://longbridge.com/en/news/298791691.md) - [zh-HK](https://longbridge.com/zh-HK/news/298791691.md) generator: "portal-rs" --- # Weekly Recap | GSK -3.53%, consensus target above spot ## The Week GSK fell 3.53% this week to close at $48.13, while the S&P 500 declined 0.8%, leaving the stock trailing the benchmark by roughly 2.73 percentage points. The four-session trading week showed a downward drift: Tuesday opened near $49 and marked the week’s high at $49.235, Thursday briefly dipped below $48 to $47.975, and Friday printed the week’s low at $47.85 before recovering to settle at $48.13. The close sits at the lower end of the 60-day range and below both the 20-day average of $50.505 and the 60-day average of $51.415. ## Key Events The most material corporate action this week was on the funding side. On 9 September, an SEC filing showed GSK priced a $6.5 billion multi-tranche notes offering, the main thread behind the week’s three substantive filings. Around the same time, GSK confirmed plans to shut a vaccine factory in Germany, putting 641 jobs at risk and signalling continued capacity adjustment. On the partnership front, Hutchmed’s exclusive development and licensing agreement with GSK on a cancer drug generated follow-on commentary, with CICC lifting Hutchmed’s target price to HK$28. Several executive compensation and shareholding disclosures also surfaced during the week, though these were largely routine. At the industry level, Hong Kong released its first five-year plan targeting biomedicine status, which could add policy attention for regional pharma names but showed limited direct read-through to GSK’s price this week. ## Analyst Ratings As of this week, 8 institutions cover GSK: 1 rates it buy, 1 rates it over, 5 rate it hold, and 1 rates it sell. The consensus recommendation is hold, with a consensus target price of $58.5775, about 21.7% above the week’s close of $48.13. The target range spans $50 to $70, with the divergence mainly at the upper end. Within the pharmaceutical industry’s 206 covered names, GSK’s ratings rank 59th, placing it in the upper-middle tier. ## The Week Ahead No GSK-specific earnings or major company events are due next week, so attention turns to US macro data and its read-through to risk appetite. The New York Fed manufacturing index arrives on 15 September, followed by retail sales and the NAHB housing market index on 16 September. Retail sales are forecast at 0.9% after a prior reading of -0.6%, and a clear miss could shift expectations around the pace of rate cuts. Separately, any further updates on the Hutchmed cancer drug collaboration or on the German plant closure could keep the company’s narrative moving into next week. ## In Short This week’s decline in GSK looks larger than the weight of company-specific news. The debt issuance and capacity adjustments are longer-term items that did little to change near-term earnings expectations. The real tension sits between price and positioning: on the latest trading day, large-lot money was a net buyer of 73.80 and medium-lot of 416.97, while large-lot outflows reached 84.98, showing some directional split. Valuation is not stretched, with a P/E of 15.22x and P/B of 4.19x, yet the stock has fallen back to the lower end of its 60-day range. The question ahead is whether macro data and sector sentiment can provide fresh direction during a quiet spell on the company calendar. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) ## Related News & Research - [GSK Wins FDA Approval For Chronic Hepatitis B Drug](https://longbridge.com/en/news/302578740.md) - [FDA approves GSK’s Hibsago as first functional cure for hepatitis B](https://longbridge.com/en/news/302675812.md) - [GSK Says Lung-Cancer Drug Shows Benefits in Global Trial](https://longbridge.com/en/news/302244451.md) - [GSK's Ris-Rez achieves 61% response rate at 8 mg/kg in early-stage lung cancer trial](https://longbridge.com/en/news/302217489.md) - [FDA approves Hibsago for chronic hepatitis B](https://longbridge.com/en/news/303202393.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**